市場調査レポート
商品コード
1629910

がん治療薬の世界市場-2025~2032年

Global Cancer Therapeutics Market - 2025-2032


出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.96円
がん治療薬の世界市場-2025~2032年
出版日: 2024年12月30日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

がん治療薬の世界市場は、2024年に1,681億5,000万米ドルに達し、2032年には4,916億米ドルに達すると予測され、予測期間2025~2032年のCAGRは12.6%で成長する見込みです。

がん治療薬には、がん細胞を標的としてその増殖を阻害し、最終的には腫瘍の進行を阻害することを目的とした幅広い治療法が含まれます。最も一般的な治療法には、標的療法、化学療法、放射線療法などがあります。化学療法は、急速に分裂するがん細胞を死滅させるために強力な薬剤を使用しますが、正常細胞にも影響を及ぼし、様々な副作用を引き起こす可能性があります。放射線療法は、高エネルギーの放射線を用いてがん細胞のDNAにダメージを与え、増殖や分裂を抑制します。

近年、免疫療法、標的療法、ホルモン療法、幹細胞移植などの革新的な治療法の導入により、がん治療薬の状況は大きく進化しています。免疫療法は、がん細胞をより効果的に認識し攻撃するために、身体の免疫システムを利用するものです。このアプローチは、メラノーマや肺がんなど、さまざまながんの治療で有望視されています。一方、標的療法は、がん細胞に関連する特定の分子標的に焦点を当て、健康な組織へのダメージを最小限に抑えながら、腫瘍をより正確に攻撃することを可能にします。この方法は、乳がんや大腸がんなどの治療において大きな進歩をもたらしました。

これらの新しいがん治療薬の可能性を最大限に引き出すためには、継続的な調査と臨床試験が不可欠です。例えば、2024年10月、NCIは急性骨髄性白血病と骨髄異形成症候群の患者を対象とした精密医療治療試験であるmyeloMATCHを開始しました。

市場力学:

促進要因と阻害要因

世界のがん有病率の増加

がん罹患率の増加はがん治療薬市場の重要な促進要因であり、市場の成長軌道に大きな影響を与えています。世界のがん罹患率の上昇に伴い、がん治療薬の需要は増加しており、今後も増加が見込まれます。2024年の世界保健機関(WHO)の予測によると、2050年には新たに3,500万人以上のがん患者が発生すると予測されており、2022年の推定2,000万人から77%増加しています。

2022年のアメリカがん協会の予測によると、2022年1月1日時点でがんの既往歴のあるアメリカ人は1,800万人以上(男性830万人、女性970万人)でした。このようながん罹患率の急増により、がん治療薬における研究開発への注目が高まり、新たな治療法の発見と開発のために多額の投資が行われています。

さらに、一般市民やヘルスケア専門家の間でがんやその治療に対する認識が高まっているため、タイムリーな診断や治療を求める人が増えており、がん治療薬の需要が高まっています。早期検診の促進や治療へのアクセス改善を目的とした政府の取り組みは、患者が遅かれ早かれ治療を受けることを促すため、この動向をさらに後押ししています。したがって、上記の要因ががん治療薬市場の成長を促進すると予想されます。

ジェネリック医薬品の存在

ジェネリック医薬品の存在は、いくつかの点でがん治療薬市場の妨げになると予想されます。ジェネリック医薬品は一般的にコストを下げ、治療へのアクセスを向上させますが、ジェネリック医薬品の導入はブランド医薬品の大幅な価格引き下げにつながり、革新的な治療法を開発する製薬企業の収益に影響を与える可能性があります。ジェネリック医薬品が普及すると競争が激化し、先発医薬品メーカーは競争力を維持するために価格の引き下げを余儀なくされます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 世界的にがんの罹患率が増加
    • 抑制要因
      • ジェネリック医薬品の存在
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 特許分析
  • 規制分析
  • SWOT分析
  • アンメットニーズ

第6章 治療法別

  • 標的療法
  • ホルモン療法
  • 化学療法
  • 放射線治療
  • 免疫療法
  • その他(光線力学療法、その他)

第7章 がんの種類別

  • 乳がん
  • 肺がん
  • 前立腺がん
  • 血液がん
  • 子宮頸がん
  • 悪性髄膜腫
  • 頭頸部がん
  • その他

第8章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第9章 エンドユーザー別

  • 病院
  • がんセンター
  • 研究機関

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • F. Hoffmann-La Roche AG
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Amgen Inc.
  • AstraZeneca

第13章 付録

目次
Product Code: ph8951

The global cancer therapeutics market reached US$ 168.15 billion in 2024 and is expected to reach US$ 491.60 billion by 2032, growing at a CAGR of 12.6% during the forecast period 2025-2032.

Cancer therapeutics encompass a wide range of treatments designed to target and disrupt the growth of cancer cells, ultimately aiming to impede tumor progression. The most common therapies include targeted therapy, chemotherapy and radiotherapy among others. Chemotherapy utilizes powerful medications to kill rapidly dividing cancer cells, but it can also affect normal cells, leading to various side effects. Radiotherapy employs high-energy radiation to damage the DNA of cancer cells, thereby inhibiting their ability to grow and divide.

In recent years, the landscape of cancer therapeutics has evolved significantly with the introduction of innovative therapies such as immunotherapy, targeted therapy, hormonal therapy, and stem cell transplants. Immunotherapy harnesses the body's immune system to recognize and attack cancer cells more effectively. This approach has shown promise in treating various cancers, including melanoma and lung cancer. Targeted therapy, on the other hand, focuses on specific molecular targets associated with cancer cells, allowing for a more precise attack on tumors while minimizing damage to healthy tissues. This method has led to significant advancements in treating cancers like breast and colorectal cancer.

Ongoing research and clinical trials are crucial for exploring the full potential of these newer cancer therapeutics. For instance, in October 2024, NCI launched myeloMATCH, a precision medicine treatment trial for people with acute myeloid leukemia and myelodysplastic syndromes.

Market Dynamics: Drivers & Restraints

Increasing prevalence of cancers globally

The increasing prevalence of cancer is a significant driver of the cancer therapeutics market, significantly impacting its growth trajectory. With the rising cancer rates globally, the demand for cancer therapeutics is rising and is expected to rise. According to the World Health Organization projections in 2024, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022.

According to the American Cancer Society projections in 2022, more than 18 million Americans (8.3 million males and 9.7 million females) with a history of cancer were alive on January 1, 2022. This surge in cancer incidence has led to a greater focus on research and development in cancer therapeutics, with substantial investments being made to discover and develop new treatment modalities.

Moreover, increased awareness of cancer and its treatments among the public and healthcare professionals is driving more individuals to seek timely diagnosis and therapy which is rising demand for cancer therapeutics. Government initiatives aimed at promoting early screening and improving access to care further support this trend, as they encourage patients to pursue treatment sooner rather than later. Thus, the above factors are expected to drive the cancer therapeutics market growth.

Presence of generic drugs

The availability of generic drugs is expected to hinder the cancer therapeutics market in several ways. While generics typically lower costs and improve access to treatments, their introduction can lead to significant price reductions for branded drugs, which may impact the revenue of pharmaceutical companies that develop innovative therapies. As generics become more prevalent, they intensify competition, forcing branded drug manufacturers to reduce prices to remain competitive.

Segment Analysis

The global cancer therapeutics market is segmented based on therapy, cancer type, distribution channel, end-user, and region.

Type:

Targeted therapy segment is expected to dominate the global cancer therapeutics market share

The targeted therapy segment is expected to dominate the cancer therapeutics market in the forecasting period in the cancer therapeutics market. This growth is attributed to its ability to specifically target cancer cells while minimizing damage to healthy cells, which enhances treatment efficacy and reduces side effects. Targeted therapies include a range of approaches such as gene expression modulators making them versatile in addressing various cancer types.

Additionally, the targeted therapy segment is expected to experience growth due to ongoing advancements in drug development and a growing understanding of cancer biology. As researchers continue to identify specific molecular targets associated with different cancers, the effectiveness of these therapies is expected to improve, further driving their adoption. For instance, in September 2022, Eli Lilly and Company received the accelerated US Food and Drug Administration approval for selpercatinib (Retevmo) for the treatment of adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion.

In June 2024, Bristol Myers Squibb received the U.S. Food and Drug Administration (FDA) accelerated approval of Augtyro (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

While other segments like chemotherapy, immunotherapy, hormonal therapy, and radiotherapy also play significant roles in cancer treatment, targeted therapies are increasingly favored for their precision and personalized approach. Thus, the above factors are expected to hold the segment in the dominant position in the global cancer therapeutics market.

Geographical Analysis

North America is expected to hold a significant position in the global cancer therapeutics market share

North America is expected to hold a dominant position in the global cancer therapeutics market due to several key factors. One of the primary drivers is the strong presence of major biopharmaceutical companies that are investing in research and development of innovative cancer therapeutics. These companies are pivotal in introducing innovative drugs and advancing cancer therapies, particularly in targeted treatments and immunotherapies.

The companies are gaining approvals for innovative drugs with increased applications. The frequent approval of new products by the FDA ensures that patients have access to the latest advancements in cancer care. For instance, in March 2022, Bristol Myers Squibb Co. announced that the U.S. Food and Drug Administration approved relatlimab from a class known as LAG-3 inhibitors - short for lymphocyte-activation gene 3 - for use in combination with Bristol's blockbuster immunotherapy Opdivo as an initial treatment for advanced melanoma.

In November 2023, Merck received the U.S. Food and Drug Administration (FDA) approval KEYTRUDA, Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Additionally, companies are entering into strategic partnerships and collaborations to expand their cancer therapeutics product portfolio and presence in various regions. For instance, in October 2024, AbbVie and EvolveImmune Therapeutics announced a collaboration and option-to-license agreement to develop multispecific biologics for multiple targets in oncology. The discovery partnership will leverage EvolveImmune's T-cell engager platform to develop novel antibody-based therapies for solid and hematologic malignancies.

Moreover, there is a growing awareness of cancer among healthcare professionals and the general public. This increasing awareness fosters early diagnosis and treatment, which are vital for improving patient outcomes. As more individuals recognize the importance of seeking timely medical attention, the demand for cancer therapies continues to rise. Thus, North America is expected to dominate the cancer therapeutics market.

Asia Pacific is growing at the fastest pace in the global cancer therapeutics market

Asia-Pacific is currently experiencing the fastest growth in the cancer therapeutics market due to the rising prevalence of different cancers in the region and the increasing investments in research and development focused on targeted therapies and immunotherapies, which are gaining prominence due to their effectiveness and reduced side effects. Expansion of the cancer therapeutics portfolio by the companies could increase the region's share cancer therapeutics market growth.

Competitive Landscape

The major global players in the cancer therapeutics market include F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie Inc., Astellas Pharma Inc., Pfizer, Inc., Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Amgen Inc. and AstraZeneca and Pfizer Inc. among others.

Key Developments

  • In January 2023, Loxo@Lilly, received the U.S. Food and Drug Administration (FDA) approval Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.
  • In May 2024, Amgen Inc. received the Food and Drug Administration's accelerated approval for tarlatamab-dlle for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Cancer Therapeutics Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Therapy
  • 3.2. Snippet by Cancer Type
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of cancers globally
    • 4.1.2. Restraints
      • 4.1.2.1. Presence of generic drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Therapy

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 6.1.2. Market Attractiveness Index, By Therapy
  • 6.2. Targeted Therapy*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Hormonal Therapy
  • 6.4. Chemotherapy
  • 6.5. Radiotherapy
  • 6.6. Immunotherapy
  • 6.7. Others (Photodynamic Therapy, Others)

7. By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 7.1.2. Market Attractiveness Index, By Cancer Type
  • 7.2. Breast Cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Lung Cancer
  • 7.4. Prostate Cancer
  • 7.5. Blood Cancer
  • 7.6. Cervical Cancer
  • 7.7. Malignant Meningioma
  • 7.8. Head and Neck Cancer
  • 7.9. Others

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies
  • 8.5. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Cancer Centers
  • 9.4. Research Institutes

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. F. Hoffmann-La Roche AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Bristol-Myers Squibb Company
  • 12.3. AbbVie Inc.
  • 12.4. Astellas Pharma Inc.
  • 12.5. Pfizer, Inc.
  • 12.6. Novartis AG
  • 12.7. Merck & Co., Inc.
  • 12.8. Eli Lilly and Company
  • 12.9. Amgen Inc.
  • 12.10. AstraZeneca

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us